Surgical Site Infections Market Forecast
DelveInsight’s Surgical Site Infections Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
LAS VEGAS, NV, UNITED STATES, January 22, 2025 /EINPresswire.com/ --
DelveInsight’s “Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Surgical Site Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Surgical Site Infections Market Forecast
Some of the key facts of the Market Report:
• The Surgical Site Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Findings indicate that surgical site infections occur in 2% to 4% of patients undergoing inpatient surgical procedures.
• According to the Centers for Disease Control and Prevention, surgical site infections (SSIs) are one of the most common healthcare-associated infections (HAIs), accounting for 22% of all infections. Approximately 2% to 5% of patients undergoing inpatient surgery develop an SSI.
• A positive shift in treatment options for surgical site infections (SSIs) is anticipated, fueled by the introduction of new therapies and the availability of oxygen therapy, such as Ogenix’s EPIFLO.
• Key Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others
• Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others
• The Surgical Site Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Surgical Site Infections pipeline products will significantly revolutionize the Surgical Site Infections market dynamics.
Surgical Site Infections Overview
A surgical site infection (SSI) is an infection that emerges following a surgical procedure in the specific area of the body where the surgery was performed. These infections might manifest as superficial ones, affecting solely the skin. However, some SSIs are more severe, potentially involving tissues below the skin's surface, organs, or implanted materials.
Get a Free sample for the Surgical Site Infections Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr
Surgical Site Infections Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Surgical Site Infections Epidemiology Segmentation:
The Surgical Site Infections market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
• Total Prevalence of Surgical Site Infections
• Prevalent Cases of Surgical Site Infections by severity
• Gender-specific Prevalence of Surgical Site Infections
• Diagnosed Cases of Episodic and Chronic Surgical Site Infections
Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Epidemiology Forecast
Surgical Site Infections Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Surgical Site Infections market or expected to get launched during the study period. The analysis covers Surgical Site Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Surgical Site Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Surgical Site Infections Therapies and Key Companies
• Ciprodiazole: MinaPharm Pharmaceuticals
• DFA-02 Antibiotic Gel: Duke Clinical Research Institute
• ZuraPrep: Zurex Pharma, Inc.
• Ertapenem: Merck Sharp & Dohme LLC
• XF-73: Destiny Pharma Plc
• D-PLEX: PolyPid Ltd.
• cefuroxime: GlaxoSmithKline
• Dalbavancin: Durata Therapeutics
• daptomycin: Cubist Pharmaceutical
• ZuraGard: Zurex Pharma, Inc.
Scope of the Surgical Site Infections Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others
• Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others
• Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
• Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Surgical Site Infections Unmet Needs, KOL’s views, Analyst’s views, Surgical Site Infections Market Access and Reimbursement
To know more about Surgical Site Infections companies working in the treatment market, visit @ Surgical Site Infections Clinical Trials and Therapeutic Assessment
Table of Contents
1. Surgical Site Infections Market Report Introduction
2. Executive Summary for Surgical Site Infections
3. SWOT analysis of Surgical Site Infections
4. Surgical Site Infections Patient Share (%) Overview at a Glance
5. Surgical Site Infections Market Overview at a Glance
6. Surgical Site Infections Disease Background and Overview
7. Surgical Site Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Surgical Site Infections
9. Surgical Site Infections Current Treatment and Medical Practices
10. Surgical Site Infections Unmet Needs
11. Surgical Site Infections Emerging Therapies
12. Surgical Site Infections Market Outlook
13. Country-Wise Surgical Site Infections Market Analysis (2020–2034)
14. Surgical Site Infections Market Access and Reimbursement of Therapies
15. Surgical Site Infections Market Drivers
16. Surgical Site Infections Market Barriers
17. Surgical Site Infections Appendix
18. Surgical Site Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
